title: Can an immune-regulatory vaccine prevent HIV infection?
abstract: Developing vaccines to prevent the establishment of HIV infection has been fraught with difficulties. It might therefore be important to consider other new strategies. Since several studies suggest that anti-inflammatory stimuli can protect from HIV infection and because HIV replicates preferably in activated T cells, we suggest here that the reduction of immune activation through a HIV-specific regulatory T-cell vaccine might thwart early viral replication. Thus, because immune activation is a good predictor of disease progression and the immune activation set point has been shown to be an early event during HIV infection, vaccinating to achieve control of early virus-specific immune activation might be advantageous.
authors.affiliation: Division of Developmental Immunology at the La Jolla Institute for Allergy & Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
authors.forename: Tobias
authors.initials: T
authors.lastname: Boettler
authors.forename: Edecio
authors.initials: E
authors.lastname: Cunha-Neto
authors.forename: Jorge
authors.initials: J
authors.lastname: Kalil
authors.forename: Matthias
authors.initials: M
authors.lastname: von Herrath
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D056747:Immunomodulation; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014779:Virus Replication / Q000276:immunology
chemical_list: D016915:AIDS Vaccines